Hello, everyone, and welcome to this edition of Excelsior Solutions’ ICER Update. Here is this week’s ICER recap:
1. ICER released a Draft Evidence Report assessing the comparative clinical effectiveness
and value of treatments for rheumatoid arthritis (RA).
This draft report will be open to public comment until 5pm ET on October 24, 2019. Based on stakeholder feedback, ICER may revise key assumptions and findings for its Evidence Report, which will be published on November 7, 2019. The Evidence Report will be subject to deliberation during a public meeting of the California Technology Assessment Forum (CTAF), one of ICER’s three independent evidence appraisal committees, on November 7, 2019.
EXCELSIOR ACTION POINT: Since medications used to treat RA often rank at the top of most plans most costly pharmacy benefit treatments (along with diabetes, cancer, and multiple sclerosis treatments), we recommend that all Clients take the opportunity to read this draft report, and for those so inclined, to interact directly
with ICER with your feedback and experience. The reason that ICER is so successful at what they do consists to a large degree to the extent that they solicit and incorporate feedback from the payer community.
If you would like to discuss this particular, or any prior, ICER report, or any other aspects of your Pharmacy Benefit Plan, simply reach out to your Excelsior Solutions account team and we will be happy to quickly set up a call.
Until next time!
Bob Kordella, RPh, MBA